Posted in | News | Medical Sensor | Biosensors

Wearable Sensors Revolutionize Parkinson's Gait Analysis

In a recent article published in npj Digital Medicine, researchers focused on utilizing wearable sensor-based quantitative gait analysis to assess PD patients with different motor subtypes. The aim of this study was to identify objective gait biomarkers for early diagnosis, subtype differentiation, and disease severity monitoring.


Wearable Sensors Revolutionize Parkinson
The recommended objective gait features for early diagnosis, subtype differentiation, and disease monitoring are listed in this figure. TD tremor-dominant, PIGD postural instability and gait disorder, MAS more affected side, LAS less affected side, RoM range of motion, SiSt sit to stand, StSi stand to sit. 1 Gait features for early detection of both TD and PIGD (for subtype-specific early detection details, please see Fig. 3 and Supplementary Table 1); 2a Gait features for disease monitoring in TD subtype; 2b Gait features for disease monitoring in PIGD subtype; 3 Gait features for subtypes differentiation. Image Credit:


Gait impairments are prevalent and debilitating symptoms in Parkinson's disease (PD) patients, worsening as the disease progresses. Previous research has highlighted the significance of specific gait metrics, such as arm swing velocity and turning parameters, in evaluating PD-related motor impairments.

The study emphasizes the need for objective assessments to monitor disease severity in PD subtypes, enhancing the implementation of tailored treatment plans. The limitations of the study include the necessity for longitudinal research to validate gait parameters as early biomarkers and the need for further investigation into PD symptoms like freezing of gait and mild cognitive impairment.

The Current Study

Participants in this study included 44 patients with Parkinson's disease (PD) and 39 healthy controls (HC). PD patients were recruited from the outpatient center of Ruijin Hospital and diagnosed by a movement disorders specialist according to the MDS clinical diagnostic criteria.

All PD patients were in the early stage (H-Y stage: 1–2.5) and did not exhibit camptocormia, marked festination, or freezing of gait. Healthy controls were recruited from the community and were free from PD clinical manifestations.

Gait assessments were conducted using body-fixed sensors during the Timed Up and Go (TUG) test. Participants were instructed to stand up from a chair without armrests, walk comfortably for 5 meters, turn back, and sit down.

Before the formal tests, participants were given a practice session to familiarize themselves with the testing procedure. Each participant performed two consecutive walking trials, with a rest period between trials to ensure adequate recovery.

Sixty-four gait and postural-related features were collected using wearable sensors, categorized into lower body, trunk and lumbar, upper body, and postural transitions.

These features included parameters related to arm swing velocity, turning efficiency, trunk rotation range, and backswing range in lower extremities. Statistical analyses were performed to compare gait parameters among the healthy controls, tremor-dominant (TD), and postural instability gait difficulty (PIGD) groups.

The discriminatory ability of each gait variable in distinguishing between PD subtypes and healthy controls was assessed using receiver operating characteristic (ROC) analysis. The area under the curve (AUC) values were calculated to determine the discriminative value of the objective gait features. Correlations between specific gait parameters and disease severity in TD and PIGD subtypes were also investigated.

Results and Discussion

The study revealed significant gait alterations in both TD and PIGD dominant PD patients compared to healthy controls. Both PD subtypes exhibited restricted backswing range in bilateral lower extremities and the more affected side (MAS) arm, as well as reduced trunk and lumbar rotation range in the coronal plane.

Additionally, both groups showed lower turning efficiency during the TUG test. These objective gait features demonstrated high discriminative value in distinguishing PD subtypes from healthy controls, as indicated by the AUC values of 0.7~0.9 (p < 0.01) in the receiver operating characteristic analysis.

Furthermore, subtle but measurable gait differences were observed between TD and PIGD patients even before the onset of clinically apparent gait impairment. Specific gait parameters were found to be significantly associated with disease severity in both PD subtypes, highlighting the potential of these parameters as subtype-specific gait markers for disease severity monitoring.

The arm swing velocity and parameters related to turning were particularly correlated with disease severity in the PIGD group, emphasizing the importance of these metrics in evaluating motor impairments in PD.

The study's findings underscore the value of wearable sensor-based gait analysis in providing objective assessments for monitoring disease severity in PD subtypes.

By identifying gait biomarkers related to upper limbs, the study suggests the feasibility of utilizing fewer sensors, such as those in smartphones or smartwatches, for gait analysis. This approach not only reduces assessment costs but also enhances convenience and suitability across various settings, promoting continuous evaluation over time.

Moreover, the study highlights the potential of AI-based gait evaluation systems in managing PD and improving patient outcomes. The advantages of AI-based systems, including higher diagnostic accuracy, continuous monitoring, and personalized therapeutic interventions, hold promise for enhancing PD diagnosis and treatment.

By providing valuable gait biomarkers for the development of AI-based gait evaluation systems, this study contributes to the advancement of personalized treatment strategies for PD patients.


The study contributes valuable insights into gait biomarkers for the development of AI-based gait evaluation systems, potentially improving PD diagnosis and treatment.

Future research directions include longitudinal studies to validate gait parameters as early biomarkers, focused studies on specific PD symptoms, and exploration of methods to integrate key variables for enhanced clinical applicability. The findings underscore the potential of wearable sensor-based gait analysis in advancing personalized treatment strategies for PD patients.

Journal Reference

Zhang W., Ling Y., et al. (2024) Wearable sensor-based quantitative gait analysis in Parkinson’s disease patients with different motor subtypes. npj Digital Medicine 7, 169. doi: 10.1038/s41746-024-01163-z

Dr. Noopur Jain

Written by

Dr. Noopur Jain

Dr. Noopur Jain is an accomplished Scientific Writer based in the city of New Delhi, India. With a Ph.D. in Materials Science, she brings a depth of knowledge and experience in electron microscopy, catalysis, and soft materials. Her scientific publishing record is a testament to her dedication and expertise in the field. Additionally, she has hands-on experience in the field of chemical formulations, microscopy technique development and statistical analysis.    


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Jain, Noopur. (2024, July 04). Wearable Sensors Revolutionize Parkinson's Gait Analysis. AZoSensors. Retrieved on July 13, 2024 from

  • MLA

    Jain, Noopur. "Wearable Sensors Revolutionize Parkinson's Gait Analysis". AZoSensors. 13 July 2024. <>.

  • Chicago

    Jain, Noopur. "Wearable Sensors Revolutionize Parkinson's Gait Analysis". AZoSensors. (accessed July 13, 2024).

  • Harvard

    Jain, Noopur. 2024. Wearable Sensors Revolutionize Parkinson's Gait Analysis. AZoSensors, viewed 13 July 2024,


  1. Caroline McGaughey Caroline McGaughey United States says:

    My Partner, who is 66 years old, was diagnosed with Parkinson's disease last year. We noticed that he was experiencing hallucinations, slow movement, disturbed sleep, and twitchy hands and legs when at rest. He had to stop taking pramipexole (Sifrol), carbidopa/levodopa, and 2 mg of biperiden because of side effects. Our family doctor recommended a PD-5 treatment from naturalherbscentre. com, which my husband has been undergoing for several months now. Exercise has been very beneficial. He has shown great improvement with the treatment thus far. He is more active now, does more, and feels less apathetic. He has more energy and can do more activities in a day than he did before. As far as tremors I observe a progress, he improved drastically. I thought I would share my husband's story in case it could be helpful, but ultimately you have to figure out what works best for you. Salutations and well wishes

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.